Moreover, using the VEGFR2 inhibitor SU5416 and the NAB to block VEGF-A/VEGFR2 signaling, our results suggested that both VEGF-A and its receptor VEGFR2 were required for the promoting effects of PERK activation on medulloblastoma cell migration and invasion. The gene discussed is EIF2AK3; the disease is medulloblastoma.